NCT07180069Completed
Phosphate Diet Strategies to Lower Blood Phosphate in Dialysis Patients
Dietary Strategies for Hyperphosphatemia: A Randomized Controlled Study on the Effectiveness of Phosphate-Specific Interventions in Reducing Serum Phosphate Levels in Hemodialysis Patients in a Dialysis Center
Source: ClinicalTrials.gov · Last updated 18 Sept 2025
Brief summary (registry, in English)
Raised phosphate levels in the blood (hyperphosphatemia) are frequently observed in hemodialysis patients with chronic kidney failure. In addition to increasing the risk of life threatening complications like heart disease, severe bone disorders, and premature mortality, this condition also poses risks to overall health. Managing phosphate levels effectively is one of the central objectives in treating patients on dialysis. Control of dietary intake, particularly cutting out high phosphate foods, is one of the most effective ways of managing phosphate levels. Dietary restrictions can be challenging for most patients to adhere to, and effective educational tools for assisting them remain unclear. This clinical study aims to evaluate the impact of diet-derived education aimed solely at reducing phosphate levels in blood. Patients undergoing hemodialysis at a dialysis center will be randomly assigned to one of two groups. In addition to standard dietary advice, one group will receive targeted phosphate-specific dietary education which includes personalized counseling and aids to encourage selection of low-phosphate foods. The primary objective is to determine whether participants in the phosphate-specific education group achieve a greater reduction in blood phosphate levels over time as compared to those who receive standard care.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 200 (actual)
- First submitted
- 20 Jul 2025
- Start date
- 1 Oct 2024
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- Kufa University
- Diseases
- Chronic kidney disease
- NCT number
- NCT07180069
What you commit to
- Study type: Interventional
- Participants enrolled: 200
- From 1 Oct 2024 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving \<2 dialysis sessions per week or \<2 months duration
- Malabsorption conditions or prior GI surgery
- Noncompliance with medication or dialysis regimen
Other illness
- Severe mental illness or cognitive impairment
- Acute illness, infection, or hospitalization at enrollment
Age
- Age \<18 or \>60
Other
- Refusal or inability to provide consent
Who the study is looking for
- Males and females aged 18-60 years
- Stage 5 CKD patients on hemodialysis
- Receiving ≥2 weekly dialysis sessions for ≥2 months
- Written informed consent provided
- Ability (patient/caregiver) to read, write, and speak Arabic
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of kufa Coordinator of this site? Confirm its status | Najaf | Iraq | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.